Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Medical Specialties
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MDT | Medtronic PLC | 0.14% | 107.57 | 0.6% | $463.76m | |
| TMO | Thermo Fisher Scientific Inc. | 1.11% | 283.77 | 1.0% | $450.58m | |
| ABT | Abbott Laboratories | -0.26% | 79.61 | 0.8% | $313.34m | |
| ISRG | Intuitive Surgical, Inc. | 1.33% | 518.03 | 2.4% | $291.82m | |
| BSX | Boston Scientific Corporation | 0.66% | 38.23 | 1.1% | $286.68m | |
| EW | Edwards Lifesciences Corporation | 0.53% | 227.29 | 1.2% | $251.89m | |
| SYK | Stryker Corporation | 1.17% | 213.76 | 1.3% | $238.49m | |
| BDX | Becton, Dickinson and Company | 1.77% | 252.95 | 1.1% | $237.90m | |
| ALGN | Align Technology, Inc. | 3.09% | 200.16 | 6.3% | $232.01m | |
| BAX | Baxter International Inc. | 0.46% | 88.01 | 1.7% | $226.86m | |
| PODD | Insulet Corporation | -0.98% | 153.39 | 6.9% | $161.71m | |
| ZBH | Zimmer Biomet Holdings, Inc. | 1.77% | 136.44 | 1.7% | $143.34m | |
| WAT | Waters Corporation | 1.17% | 213.77 | 4.0% | $124.80m | |
| PEN | Penumbra, Inc. | 2.27% | 145.95 | 8.7% | $110.33m | |
| ABMD | ABIOMED, Inc. | 4.50% | 169.64 | 3.3% | $105.68m |
Company Profile
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease, and other cardiovascular disorders including structural heart conditions. The Rhythm Management segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal, and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.